<DOC>
	<DOCNO>NCT01025206</DOCNO>
	<brief_summary>This first human study ass safety tolerability monoclonal antibody ICAM-1 patient Multiple Myeloma . The tumour response rate also measure .</brief_summary>
	<brief_title>A Study Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody , Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Advanced Myeloma measurable disease least 2 previous regimen . Life expectancy &gt; 3 month . Performance status ECOG &lt; 2 . Prior antineoplastic therapy within 4 week prior inclusion . No high dose steroid within 7 day prior screen . Severe condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>